Nanobiotix is transforming into a capital-light oncology platform focused on milestone and royalty revenues, centered on its JNJ-1900 program now led by Johnson & Johnson. JNJ-1900 aims to enhance radiotherapy across multiple solid tumors, with a potential $2.6 billion milestone structure and double-digit royalties. Recent financing and a planned equity raise in May 2026 extend Nanobiotix's cash runway through 2029, transferring much clinical and operational risk to J&J. While speculative, Nanobiotix offers upside if its radiotherapy platform gains broad adoption but faces risks including clinical trial outcomes, operational challenges, and dilution from fundraising.
Kroger reported mixed Q2 earnings with adjusted EPS of $1.09 beating estimates, but revenues slightly below expectations at $34.62 billion. Despite slower sales growth, Kroger maintained its full-year adjusted EPS guidance of $5.10 to $5.30, supporte...
Enbridge Inc. is expanding its crude oil infrastructure by acquiring Tallgrass Energy's crude oil business for $2.55 billion. This move strengthens its presence in key U.S. oil regions and is funded partly by a recent $3 billion public offering. Desp...
RF Industries reported a record quarterly revenue of $23.96 million, a 21% increase from last year, surpassing analyst expectations. Although earnings per share slightly missed estimates at $0.19 versus $0.20, the company showed strong year-over-year...
Morgan Stanley analyst Joe Laetsch raised Valero Energy's price target to $411, signaling a potential 3.18% upside from its current price. Institutional investors like Virginia Retirement Systems and Gamco Investors are initiating new positions, whil...
Meta Platforms' stock surged over 21% in 27 days due to resolving social media lawsuits and launching its AI platform Muse. Goldman Sachs analyst Eric Sheridan maintained a 'Buy' rating and a $725 price target, signaling a potential 9.22% rise from c...
